Johnson & Johnson (NYSE:JNJ – Get Free Report) EVP Elizabeth Forminard sold 13,072 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the sale, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,832,923.66. The trade was a 43.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Johnson & Johnson Stock Up 0.8%
Shares of JNJ stock traded up $2.26 during midday trading on Friday, reaching $285.78. 6,279,519 shares of the stock were exchanged, compared to its average volume of 7,472,752. Johnson & Johnson has a 1 year low of $193.55 and a 1 year high of $288.11. The firm has a market cap of $687.95 billion, a PE ratio of 43.30, a price-to-earnings-growth ratio of 2.80 and a beta of 0.22. The company’s 50 day moving average is $266.97 and its two-hundred day moving average is $249.85. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. During the same quarter last year, the business posted $2.80 EPS. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities research analysts predict that Johnson & Johnson will post 11.12 EPS for the current year.
Johnson & Johnson Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio is 81.21%.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on JNJ. TD Cowen restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 20th. JPMorgan Chase & Co. upped their target price on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 29th. HSBC increased their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Royal Bank Of Canada dropped their price objective on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 14th. Finally, Argus set a $300.00 price objective on shares of Johnson & Johnson in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $275.92.
View Our Latest Stock Report on JNJ
Key Johnson & Johnson News
These are some of the JNJ news items that stood out recently:
- Positive Sentiment: J&J is backing Francis Medical as it advances a water-vapor prostate-cancer treatment device toward FDA premarket approval. The investment expands its reach in minimally invasive oncology treatment. J&J leads Francis Medical investment to fund prostate cancer device
- Neutral Sentiment: J&J also led a $100 million funding round for Delix Therapeutics’ depression-drug development. This broadens its exposure to emerging psychiatric treatments, but clinical-stage programs carry substantial execution risk. Johnson & Johnson Backs New Cancer Device And Leads $100 Million Depression Bet
- Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors. The notice provides no specific findings, but litigation-related uncertainty may weigh on sentiment. Pomerantz Law Firm Investigates Claims on Behalf of Johnson & Johnson Investors
Institutional Investors Weigh In On Johnson & Johnson
Institutional investors have recently modified their holdings of the business. Outlook Capital Management LLC purchased a new stake in Johnson & Johnson in the second quarter worth approximately $28,000. Matrix Trust Co raised its stake in Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after buying an additional 54 shares during the last quarter. Navigoe LLC raised its stake in Johnson & Johnson by 60.4% during the 3rd quarter. Navigoe LLC now owns 146 shares of the company’s stock valued at $38,000 after buying an additional 55 shares during the last quarter. Montgomery Financial Services LLC purchased a new stake in Johnson & Johnson during the 2nd quarter valued at $43,000. Finally, Hanseatic Management Services Inc. bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at $52,000. 69.55% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Recommended Stories
- Five stocks we like better than Johnson & Johnson
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
